Free Trial

Arbutus Biopharma (ABUS) Short Interest Ratio & Short Volume

Arbutus Biopharma logo
$3.42 -0.02 (-0.49%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$3.45 +0.03 (+0.76%)
As of 02/21/2025 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arbutus Biopharma Short Interest Data

Arbutus Biopharma (ABUS) has a short interest of 6.72 million shares. This marks a 1.20% increase in short interest from the previous month. The short interest ratio (days to cover) is 8.1, indicating that it would take 8.1 days of the average trading volume of 696,622 shares to cover all short positions.

Current Short Interest
6,720,000 shares
Previous Short Interest
6,640,000 shares
Change Vs. Previous Month
+1.20%
Dollar Volume Sold Short
$22.38 million
Short Interest Ratio
8.1 Days to Cover
Last Record Date
January 31, 2025
Outstanding Shares
189,490,000 shares
Percentage of Shares Shorted
3.55%
Today's Trading Volume
960,047 shares
Average Trading Volume
696,622 shares
Today's Volume Vs. Average
138%
Short Selling Arbutus Biopharma?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Arbutus Biopharma and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

ABUS Short Interest Over Time

ABUS Days to Cover Over Time

ABUS Percentage of Float Shorted Over Time

Arbutus Biopharma Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/31/20256,720,000 shares $22.38 million +1.2%N/A8.1 $3.33
1/15/20256,640,000 shares $21.78 million +11.6%N/A8 $3.28
12/31/20245,950,000 shares $19.46 million -0.3%N/A6.8 $3.27
12/15/20245,970,000 shares $20.78 million +2.6%N/A6.9 $3.48
11/30/20245,820,000 shares $20.14 million -4.0%N/A5.7 $3.46
11/15/20246,060,000 shares $22.06 million -7.3%N/A5.3 $3.64
10/31/20246,540,000 shares $25.15 million -16.1%N/A5.9 $3.85
10/15/20247,790,000 shares $32.02 million +5.8%N/A6.9 $4.11
9/30/20247,360,000 shares $28.34 million +12.2%N/A6.6 $3.85
9/15/20246,560,000 shares $29.32 million +8.3%N/A5.6 $4.47
8/31/20246,060,000 shares $23.45 million -8.7%N/A5.8 $3.87
8/15/20246,640,000 shares $24.90 million -2.4%N/A6.6 $3.75
7/31/20246,800,000 shares $25.64 million -3.1%N/A6.8 $3.77
7/15/20247,020,000 shares $26.33 million +16.8%N/A7.3 $3.75
6/30/20246,010,000 shares $18.57 million +11.9%N/A6.1 $3.09
6/15/20245,370,000 shares $16.86 million +6.8%N/A4.2 $3.14
5/31/20245,030,000 shares $16.90 million -5.8%N/A4.1 $3.36
5/15/20245,340,000 shares $15.01 million -8.1%N/A4.6 $2.81
4/30/20245,810,000 shares $15.86 million +12.4%N/A4.3 $2.73
4/15/20245,170,000 shares $15.35 million +13.6%N/A3.7 $2.97
3/31/20244,550,000 shares $11.74 million +10.2%N/A3.4 $2.58
3/15/20244,130,000 shares $10.82 million +1.5%N/A4.4 $2.62
2/29/20244,070,000 shares $11.40 million +10.3%N/A4.2 $2.80
2/15/20243,690,000 shares $10.74 million -39.7%N/A3.8 $2.91
1/31/20246,120,000 shares $14.50 million -4.8%N/A7.3 $2.37
1/15/20246,430,000 shares $14.85 million +3.4%N/A9.5 $2.31
12/31/20236,220,000 shares $15.55 million +0.5%N/A9.1 $2.50
12/15/20236,190,000 shares $13.87 million +0.2%N/A9.2 $2.24
11/30/20236,180,000 shares $12.67 million -8.2%N/A9.4 $2.05
11/15/20236,730,000 shares $12.38 million +6.7%N/A10.6 $1.84
10/31/20236,310,000 shares $11.55 million +9.4%N/A10.4 $1.83
10/15/20235,770,000 shares $10.73 million -16.1%N/A9.4 $1.86
9/30/20236,880,000 shares $13.97 million +18.6%N/A11.2 $2.03
9/15/20235,800,000 shares $11.83 million +12.0%N/A9.4 $2.04
8/31/20235,180,000 shares $10.52 million +0.8%N/A8.3 $2.03
8/15/20235,140,000 shares $10.23 million +5.1%N/A8.4 $1.99
7/31/20234,890,000 shares $10.61 million +0.8%N/A8.5 $2.17
7/15/20234,850,000 shares $10.82 million -0.8%N/A7.8 $2.23
6/30/20234,890,000 shares $11.25 million +12.7%N/A6.8 $2.30
6/15/20234,340,000 shares $10.59 million +2.1%N/A5.8 $2.44
Elon Social Security shock? (Ad)

“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One Boston based think tank believes it could have drastic impacts on your money and life in America.

5/31/20234,250,000 shares $10.58 million -0.9%N/A5.3 $2.49
5/15/20234,290,000 shares $10.98 million +8.3%N/A4.7 $2.56
4/30/20233,960,000 shares $9.94 million -7.0%N/A4.2 $2.51
4/15/20234,260,000 shares $12.23 million -13.9%N/A4.7 $2.87
3/31/20234,950,000 shares $15.00 million +5.5%N/A5.4 $3.03
3/15/20234,690,000 shares $14.21 million +15.8%N/A5 $3.03
2/28/20234,050,000 shares $11.26 million +1.5%N/A4.5 $2.78
2/15/20233,990,000 shares $10.85 million -7.4%N/A4.5 $2.72
1/31/20234,310,000 shares $12.97 million -8.5%N/A4.6 $3.01
1/15/20234,710,000 shares $13.42 million -0.6%N/A4.9 $2.85
12/30/20224,740,000 shares $11.04 million +23.1%N/A4.6 $2.33
12/15/20223,850,000 shares $10.43 million -4.0%N/A4.1 $2.71
11/30/20224,010,000 shares $9.42 million +7.2%N/A4.4 $2.35
11/15/20223,740,000 shares $10.43 million -10.3%N/A4.3 $2.79
10/31/20224,170,000 shares $9.76 million -0.7%N/A5.2 $2.34
10/15/20224,200,000 shares $9.20 million +2.2%N/A5.4 $2.19
9/30/20224,110,000 shares $7.85 million +7.6%N/A5.6 $1.91
9/15/20223,820,000 shares $8.82 million -2.6%N/A4.7 $2.31
8/31/20223,920,000 shares $8.70 million -11.1%N/A4.7 $2.22
8/15/20224,410,000 shares $11.16 million -7.4%N/A4.8 $2.53
7/31/20224,760,000 shares $11.00 million -7.4%N/A4.5 $2.31
7/15/20225,140,000 shares $13.06 million -2.5%N/A4.8 $2.54
6/30/20225,270,000 shares $14.28 million +7.1%N/A4.5 $2.71
6/15/20224,920,000 shares $12.55 million -7.9%N/A3.9 $2.55
5/31/20225,340,000 shares $12.98 million +6.6%N/A3.8 $2.43
5/15/20225,010,000 shares $11.57 million -5.8%N/A2.9 $2.31
4/30/20225,320,000 shares $12.40 million -8.3%N/A2.9 $2.33
4/15/20225,800,000 shares $15.95 million -12.8%N/A2.6 $2.75
3/31/20226,650,000 shares $19.82 million +0.3%N/A2.7 $2.98
3/15/20226,630,000 shares $18.96 million -8.8%N/A2.3 $2.86
2/28/20227,270,000 shares $23.26 million +3.0%N/A1.8 $3.20
2/15/20227,060,000 shares $22.95 million +4.1%N/A0.7 $3.25
1/31/20226,780,000 shares $19.05 million +73.0%N/A0.7 $2.81
1/15/20223,920,000 shares $12.98 million -13.9%N/A0.4 $3.31
12/31/20214,550,000 shares $17.70 million -43.6%N/A0.5 $3.89
12/15/20218,060,000 shares $32.97 million +253.5%N/A0.8 $4.09
11/30/20212,280,000 shares $7.30 million -4.2%N/A0.2 $3.20
11/15/20212,380,000 shares $8.00 million -15.0%N/A1 $3.36
10/29/20212,800,000 shares $11.28 million +0.7%N/A1.1 $4.03
10/15/20212,780,000 shares $11.34 million No Change3.5%1.1 $4.08
9/30/20212,780,000 shares $11.93 million -24.9%3.5%1.2 $4.29
9/15/20213,700,000 shares $15.61 million -6.1%4.6%1.6 $4.22
8/31/20213,940,000 shares $13.51 million -5.1%4.9%2.4 $3.43
8/13/20214,150,000 shares $12.74 million -26.2%5.2%2.5 $3.07
7/30/20215,620,000 shares $15.12 million +14.9%7.3%3.6 $2.69
7/15/20214,890,000 shares $12.96 million -9.6%6.3%3.1 $2.65
6/30/20215,410,000 shares $16.39 million +51.1%7.0%3.3 $3.03
6/15/20213,580,000 shares $11.38 million -14.4%4.6%2.8 $3.18
5/28/20214,180,000 shares $11.83 million -9.3%5.4%3.1 $2.83
5/14/20214,610,000 shares $11.53 million +19.4%N/A2.9 $2.50
Elon Social Security shock? (Ad)

“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One Boston based think tank believes it could have drastic impacts on your money and life in America.

4/30/20213,860,000 shares $13.55 million -8.5%N/A1.9 $3.51
4/15/20214,220,000 shares $14.01 million +1.9%N/A1.9 $3.32
3/31/20214,140,000 shares $13.04 million +6.2%N/A1.6 $3.15
3/15/20213,900,000 shares $14.78 million +19.3%N/A1.3 $3.79
2/26/20213,270,000 shares $12.46 million +28.2%N/A0.8 $3.81
2/12/20212,550,000 shares $11.17 million -20.1%N/A0.6 $4.38
1/29/20213,190,000 shares $11.71 million -21.2%N/A0.8 $3.67
1/15/20214,050,000 shares $16.32 million -16.0%N/A1.2 $4.03
12/31/20204,820,000 shares $17.93 million +63.4%N/A1.5 $3.72
12/15/20202,950,000 shares $14.40 million +37.9%N/A1 $4.88
11/30/20202,140,000 shares $9.29 million -2.3%N/A1.1 $4.34
11/15/20202,190,000 shares $7.95 million -17.7%N/A1.3 $3.63
10/30/20202,660,000 shares $7.82 million +32.3%N/A1.4 $2.94
10/15/20202,010,000 shares $6.35 million -36.2%N/A0.6 $3.16
9/30/20203,150,000 shares $9.86 million +4.7%N/A0.3 $3.13
9/15/20203,010,000 shares $8.85 million +14.9%N/A0.3 $2.94
8/31/20202,620,000 shares $7.62 million -0.8%N/A0.3 $2.91
8/14/20202,640,000 shares $9.16 million +34.0%N/A0.3 $3.47
7/31/20201,970,000 shares $7.51 million +157.5%3.9%0.2 $3.81
7/15/2020765,100 shares $1.45 million +19.3%1.6%0.1 $1.89
6/30/2020641,200 shares $1.23 million +11.8%1.3%0.6 $1.92
6/15/2020573,400 shares $1.06 million +1.4%1.2%0.5 $1.84
5/29/2020565,300 shares $1.23 million +31.5%1.1%0.5 $2.17
5/15/2020429,900 shares $902,790.00 +4.9%0.9%0.4 $2.10
4/30/2020409,800 shares $475,368.00 +18.8%0.9%0.5 $1.16
4/15/2020345,000 shares $410,550.00 -34.6%0.8%0.4 $1.19
3/31/2020527,700 shares $638,517.00 -6.6%1.2%0.7 $1.21
3/13/2020564,800 shares $581,744.00 -4.8%1.5%1.8 $1.03
2/28/2020593,100 shares $978,615.00 +1.9%1.5%0.9 $1.65

ABUS Short Interest - Frequently Asked Questions

What is Arbutus Biopharma's current short interest?

Short interest is the volume of Arbutus Biopharma shares that have been sold short but have not yet been covered or closed out. As of January 31st, investors have sold 6,720,000 shares of ABUS short. Learn More on Arbutus Biopharma's current short interest.

What is a good short interest ratio for Arbutus Biopharma?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ABUS shares currently have a short interest ratio of 8.0. Learn More on Arbutus Biopharma's short interest ratio.

Which institutional investors are shorting Arbutus Biopharma?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Arbutus Biopharma: GTS Securities LLC, Wolverine Trading LLC, Squarepoint Ops LLC, Group One Trading LLC, Caption Management LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Arbutus Biopharma's short interest increasing or decreasing?

Arbutus Biopharma saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 6,720,000 shares, an increase of 1.2% from the previous total of 6,640,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Arbutus Biopharma's short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Arbutus Biopharma: HUTCHMED (China) Limited (0.24%), Edgewise Therapeutics, Inc. (11.31%), Mirum Pharmaceuticals, Inc. (13.69%), Amneal Pharmaceuticals, Inc. (1.87%), Kymera Therapeutics, Inc. (11.87%), Protagonist Therapeutics, Inc. (6.36%), Mesoblast Limited (1.61%), Centessa Pharmaceuticals plc (3.38%), Bausch Health Companies Inc. (2.37%), Harmony Biosciences Holdings, Inc. (9.32%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks.

What does it mean to sell short Arbutus Biopharma stock?

Short selling ABUS is an investing strategy that aims to generate trading profit from Arbutus Biopharma as its price is falling. ABUS shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Arbutus Biopharma?

A short squeeze for Arbutus Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ABUS, which in turn drives the price of the stock up even further.

How often is Arbutus Biopharma's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABUS, twice per month. The most recent reporting period available is January, 31 2025.




This page (NASDAQ:ABUS) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners